Want to see SE:SANION full AI Analyst Report?
Top Page
Saniona AB
(SANION)
Select Model
Select Model
Rating:64Neutral
Price Target:
kr11.00
▼(-5.25% Downside)
Action:Reiterated
Date:08/28/26
The score is primarily supported by improved financial strength (high recent profitability, positive free cash flow, and a debt-free balance sheet) and a low P/E valuation. These positives are meaningfully offset by weak technicals (below major moving averages and negative MACD) and high business volatility, highlighted by sharply negative TTM revenue growth and inconsistent cash conversion.
Positive Factors
Strong current profitability
The sharp move from heavy losses in 2021–2023 to strong profitability in 2025 and the latest TTM improves internal funding capacity and supports continued development. If maintained, higher margins can provide resilience while Saniona advances its pipeline and pursues partnerships.
Negative Factors
Highly volatile revenue base
The sharp reversal in revenue performance makes current earnings less predictable and raises questions about how much profitability reflects recurring operations versus milestone or licensing income. Such volatility can complicate planning, reduce visibility into future funding capacity, and weaken confidence in sustained growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong current profitability
The sharp move from heavy losses in 2021–2023 to strong profitability in 2025 and the latest TTM improves internal funding capacity and supports continued development. If maintained, higher margins can provide resilience while Saniona advances its pipeline and pursues partnerships.
Read all positive factors
Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.47B
Dividend YieldN/A
Average Volume (3M)419.52K
Price to Earnings (P/E)7.6
Beta (1Y)0.37
Revenue Growth24.98%
EPS Growth-31.44%
CountrySE
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.34
Shares Outstanding138,030,140
10 Day Avg. Volume559,036
30 Day Avg. Volume419,525
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr267.00M
Saniona AB Business Overview & Revenue Model
Company Description
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system dis...
How the Company Makes Money
Saniona makes money primarily through partnering/licensing its drug discovery and development programs to other pharmaceutical/biotechnology companies and through raising capital to fund operations.
Key revenue streams:
- Collaboration and licens...
Saniona AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 424.56M | 434.40M | 334.67M | 16.84M | 15.28M | 10.48M |
| Gross Profit | 263.78M | 286.37M | 329.58M | 11.78M | 10.81M | 5.85M |
| EBITDA | 209.32M | 314.46M | 251.90M | -68.28M | -198.41M | -398.86M |
| Net Income | 183.53M | 284.67M | 188.71M | -95.81M | -245.36M | -410.90M |
Balance Sheet | ||||||
| Total Assets | 600.98M | 679.74M | 339.73M | 64.14M | 153.70M | 440.25M |
| Cash, Cash Equivalents and Short-Term Investments | 486.31M | 580.82M | 303.26M | 30.96M | 111.71M | 356.86M |
| Total Debt | 0.00 | 0.00 | 10.50M | 71.41M | 81.52M | 99.77M |
| Total Liabilities | 52.77M | 44.58M | 107.92M | 86.08M | 100.99M | 158.25M |
| Stockholders Equity | 548.22M | 635.16M | 231.82M | -21.94M | 52.71M | 282.00M |
Cash Flow | ||||||
| Free Cash Flow | 187.39M | 200.30M | 249.07M | -85.66M | -282.52M | -346.52M |
| Operating Cash Flow | 193.65M | 273.86M | 249.20M | -85.53M | -281.54M | -345.04M |
| Investing Cash Flow | -13.52M | -77.62M | -124.00K | -129.00K | 6.84M | 43.16M |
| Financing Cash Flow | -722.26K | 108.19M | 23.25M | -7.97M | -20.52M | 50.60M |
Saniona AB Technical Analysis
Negative
11.61
Price Trends
12.73
Negative
13.15
Negative
16.53
Negative
Market Momentum
-0.56
Positive
25.93
Positive
17.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Negative. The current price of 11.61 is below the 20-day moving average (MA) of 11.82, below the 50-day MA of 12.73, and below the 200-day MA of 16.53, indicating a bearish trend. The MACD of -0.56 indicates Positive momentum. The RSI at 25.93 is Positive, neither overbought nor oversold. The STOCH value of 17.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SANION.
Saniona AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | kr35.76B | 51.27 | 15.54% | ― | <0.01% | -6.75% | |
69 Neutral | kr29.00B | 268.57 | 5.18% | 0.67% | -46.09% | -90.13% | |
64 Neutral | kr1.47B | 7.57 | 29.71% | ― | 24.98% | -31.44% | |
56 Neutral | kr4.27B | -5.15 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.16B | 54.79 | 65.99% | ― | ― | ― |
* Healthcare Sector Average
SE:SANION
Saniona AB
10.15
-1.75
-14.71%
SE:HNSA
Hansa Biopharma AB
40.50
11.24
38.41%
SE:MVIR
Medivir AB
1.82
-0.09
-4.51%
SE:CAMX
Camurus AB
584.00
-147.50
-20.16%
SE:ALZCUR
AlzeCure Pharma AB
8.18
5.60
216.69%
SE:BIOA.B
BioArctic AB Class B
319.60
50.79
18.90%
Saniona AB Corporate Events
Saniona Narrows R&D Focus as Losses Widen but Cash Position Strengthens
Aug 27, 2026
Saniona reported a sharp year-on-year decline in revenue and a significantly wider operating loss for the first half of 2026, even as its cash and cash equivalents rose to SEK 486.3 million, indicating a strengthened balance sheet despite deepenin...
Saniona Schedules Q2 Investor Call for 27 August 2026
Aug 20, 2026
Saniona AB has invited investors to join its Q2 investor call on 27 August 2026 at 11:00 CEST, where management will present quarterly results and a broader company update. The event, hosted via Redeye with a webcast replay available on the compan...
AstronauTx Takes Global Rights to Saniona Neurology Program as ATX0926 Moves Toward Clinic
Aug 10, 2026
Saniona and U.K.-based biotechnology firm AstronauTx have advanced their 2023 collaboration to a new stage, with AstronauTx exercising its option to acquire exclusive worldwide rights to a neurological disease program based on a novel ion channel ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.